Acute Lung Injury - Pipeline Review, H2 2013:Industry Analysis Report @ http://www.researchmoz.us/acute-lung-injury-pipeline-review-h2-2013-report.html

1. Acute Lung Injury - Pipeline Review, H2 2013
Global Markets Directs, 'Acute Lung Injury Pipeline Review, H2 2013', provides an overview of the
indications therapeutic pipeline. This report provides information on the therapeutic development for Acute
Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Acute Lung Injury. Acute Lung Injury
Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs
proprietary databases, Company/University websites, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party sources, put together by Global
Markets Directs team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of
data for the indicated disease.
Scope
A snapshot of the global therapeutic scenario for Acute Lung Injury. A review of the Acute Lung Injury
products under development by companies and universities/research institutes based on information derived
from company and industry-specific sources. Coverage of products based on various stages of development
ranging from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and
combined therapeutics. Coverage of the Acute Lung Injury pipeline on the basis of route of administration and
molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products.
Reasons to buy
Identify and understand important and diverse types of therapeutics under development for Acute Lung
Injury. Identify emerging players with potentially strong product portfolio and design effective
counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying
players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding
Acute Lung Injury pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and
out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and
expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
table Of Contents
table Of Contents 2
list Of Tables 6
list Of Figures 7
introduction 8
global Markets Direct Report Coverage 8
acute Lung Injury Overview 9
therapeutics Development 10
an Overview Of Pipeline Products For Acute Lung Injury 10
acute Lung Injury Therapeutics Under Development By Companies 12
Acute Lung Injury - Pipeline Review, H2 2013

2. acute Lung Injury Therapeutics Under Investigation By Universities/institutes 14
late Stage Products 16
comparative Analysis 16
mid Clinical Stage Products 17
comparative Analysis 17
early Clinical Stage Products 18
comparative Analysis 18
discovery And Pre-clinical Stage Products 19
comparative Analysis 19
acute Lung Injury Therapeutics - Products Under Development By Companies 20
acute Lung Injury Therapeutics - Products Under Investigation By Universities/institutes 21
companies Involved In Acute Lung Injury Therapeutics Development 22
glaxosmithkline Plc 22
quark Pharmaceuticals, Inc. 23
discovery Laboratories, Inc. 24
silence Therapeutics Plc. 25
altor Bioscience Corporation 26
mondobiotech Holding Ag 27
polyphor Ltd. 28
implicit Bioscience Limited 29
kyorin Pharmaceutical Co., Ltd. 30
techpool Bio-pharma Co., Ltd. 31
mayo Clinic 32
faron Pharmaceuticals, Ltd. 33
apeptico Forschung Und Entwicklung Gmbh 34
acute Lung Injury - Therapeutics Assessment 35
assessment By Monotherapy Products 35
assessment By Route Of Administration 36
assessment By Molecule Type 38
drug Profiles 41
pol-6014 - Drug Profile 41
product Description 41
mechanism Of Action 41
r&d Progress 41
dilmapimod - Drug Profile 43
product Description 43
mechanism Of Action 43
r&d Progress 43
lucinactant - Drug Profile 45
product Description 45
mechanism Of Action 45
r&d Progress 45
alt-836 - Drug Profile 47
Acute Lung Injury - Pipeline Review, H2 2013

3. product Description 47
mechanism Of Action 47
r&d Progress 47
respiratory And Inflammatory Diseases Program - Drug Profile 49
product Description 49
mechanism Of Action 49
r&d Progress 49
krp-109 - Drug Profile 50
product Description 50
mechanism Of Action 50
r&d Progress 50
gsk-2586881 - Drug Profile 51
product Description 51
mechanism Of Action 51
r&d Progress 51
etanercept - Drug Profile 52
product Description 52
mechanism Of Action 52
r&d Progress 52
atu-111 - Drug Profile 53
product Description 53
mechanism Of Action 53
r&d Progress 53
interferon Beta-1a - Drug Profile 54
product Description 54
mechanism Of Action 54
r&d Progress 54
interferon Beta-1a - Drug Profile 56
product Description 56
mechanism Of Action 56
r&d Progress 56
aspirin - Drug Profile 58
product Description 58
mechanism Of Action 58
r&d Progress 58
rosuvastatin Calcium - Drug Profile 59
product Description 59
mechanism Of Action 59
r&d Progress 59
atu-134 - Drug Profile 60
product Description 60
mechanism Of Action 60
r&d Progress 60
Acute Lung Injury - Pipeline Review, H2 2013

4. pancyte - Drug Profile 61
product Description 61
mechanism Of Action 61
r&d Progress 61
ap-301 - Drug Profile 63
product Description 63
mechanism Of Action 63
r&d Progress 63
gsk-1995057 - Drug Profile 65
product Description 65
mechanism Of Action 65
r&d Progress 65
ct-2009 - Drug Profile 66
product Description 66
mechanism Of Action 66
r&d Progress 66
daskloster-1000-04 - Drug Profile 67
product Description 67
mechanism Of Action 67
r&d Progress 67
daskloster-014101 - Drug Profile 68
product Description 68
mechanism Of Action 68
r&d Progress 68
isoflurane - Drug Profile 69
product Description 69
mechanism Of Action 69
r&d Progress 69
t-0901317 - Drug Profile 70
product Description 70
mechanism Of Action 70
r&d Progress 70
drug Targeting Leptin - Drug Profile 71
product Description 71
mechanism Of Action 71
r&d Progress 71
stromal Cell Therapy For Acute Lung Injury - Drug Profile 72
product Description 72
mechanism Of Action 72
r&d Progress 72
tp-405 - Drug Profile 73
product Description 73
mechanism Of Action 73
Acute Lung Injury - Pipeline Review, H2 2013

5. r&d Progress 73
xib-1301 - Drug Profile 74
product Description 74
mechanism Of Action 74
r&d Progress 74
drug Targeting Urokinase Plasminogen Activator - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
mesenchymal Stem Cells - Drug Profile 76
product Description 76
mechanism Of Action 76
r&d Progress 76
drug Inhibiting Igf-1r - Drug Profile 77
product Description 77
mechanism Of Action 77
r&d Progress 77
tat-snap-23 - Drug Profile 78
product Description 78
mechanism Of Action 78
r&d Progress 78
rpai-1 - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
s-1226 - Drug Profile 80
product Description 80
mechanism Of Action 80
r&d Progress 80
s-1229 - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
acute Lung Injury Therapeutics - Drug Profile Updates 82
acute Lung Injury Therapeutics - Discontinued Products 90
acute Lung Injury Therapeutics - Dormant Products 91
acute Lung Injury - Product Development Milestones 92
featured News & Press Releases 92
oct 08, 2013: Discovery Labs Announces Notice Of Allowance For A U.s. Patent Supporting The Aerosurf
Development Program 92
sep 09, 2013: New Data From The Ali/ards Fpcli001 Study Presented At The 2013 European Respiratory
Society Meeting 92
nov 01, 2012: Faron Pharma Receives 375,000 Grant From Tekes For Traumakine Program 93
Acute Lung Injury - Pipeline Review, H2 2013

6. sep 27, 2012: Discovery Labs Initiates Research Projects With Research Institutions And Us Government
Agencies To Assess Kl(4) Surfactant Utility In Acute Lung Injury 93
sep 10, 2012: Silence Therapeutics' Proof Of Concept Study In Preclinical Model Shows Survival Benefit
With Atu111 In Combination With Antibiotics 94
may 21, 2012: Faron Pharma Announces Presentation Of New Data From Ali/ards Fpcli001 Study At 2012
Americanthoracic Society Meeting 95
jan 20, 2012: Carolus Therapeutics Reports Publication Of Preclinical Data For Ct-2009 Supporting
Development In Acute Lung Injury 95
dec 19, 2011: Apeiron Biologics Announces Initiation Of Phase Iia Study In Acute Lung Injury Patients 96
nov 08, 2011: Silence Provides Development Update Of Atu134 96
oct 07, 2011: Faron Completes Phase I/ii Clinical Trial With Fp-1201 In Acute Lung Injuries 97
appendix 98
methodology 98
coverage 98
secondary Research 98
primary Research 98
expert Panel Validation 98
contact Us 99
disclaimer 99
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Acute Lung Injury - Pipeline Review, H2 2013